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Abstract
Background: Only 7.8 % of individuals meeting diagnostic criteria for alcohol use disorder (AUD) receive treatment
in a given year. Most individuals with AUDs are identified in primary care (PC) settings and referred to substance
use disorders (SUD) clinics; however, only a minority of those referred attend treatment services. Safe and effective
pharmacological treatments for AUD exist, but they are rarely prescribed by PC providers. The objective of this
study is to refine, implement, and evaluate an intervention to integrate pharmacological AUD treatment options
into PC settings. This paper provides a detailed description of the intervention design and the evaluation
components.
Methods/design: Three large Veterans Health Administration (VHA) facilities are participating in the intervention.
The intervention targets stakeholder groups with tailored strategies based on implementation theory and prior
research identifying barriers to implementation of AUD pharmacotherapy. Local SUD providers and primary care
mental health integration (PCMHI) providers are trained to serve as local implementation/clinical champions and
receive external facilitation. PC providers receive access to consultation from local and national clinical champions,
educational materials, and a dashboard of patients with AUD on their caseloads for case identification. Veterans
with AUD diagnoses receive educational information in the mail just prior to a scheduled PC visit. Effectiveness of
the intervention will be evaluated through an interrupted time series with matched controls to monitor change in
facility level AUD pharmacotherapy prescribing rates. Following Stetler’s four-phase formative evaluation (FE)
strategy, FE methods include (1) developmental FE (pre-implementation interviews with champions, PC providers,
and Veterans), (2) implementation-focused FE (tracking attendance at facilitation meetings, academic detailing
efforts by local champions, and patient dashboard utilization), (3) progress-focused FE (tracking rates of AUD
pharmacotherapy prescribing and rates of referral to PCMHI and SUD specialty care), and (4) interpretive FE (postimplementation interviews with champions and PC providers). Analysis of FE data will be guided by the
Consolidated Framework for Implementation Research (CFIR).
Discussion: If demonstrated to be successful, this implementation strategy will provide a replicable, feasible, and
relative low-cost method for integrating AUD treatment services into PC settings, thereby increasing access to AUD
treatment.
Keywords: Alcohol use disorder treatment, Alcohol use disorder pharmacotherapy, Primary care mental health
integration, Implementation
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Background
The ADAPT-PC protocol provides a detailed description
of an intervention to improve access to evidence-based
pharmacological treatments for alcohol use disorders
(AUD) in primary care settings that was designed to be
easily scalable and relatively inexpensive. The protocol
also provides a detailed description of how implementation frameworks and methods can be used to inform the
design, refinement, and evaluation of an implementation
intervention.
In 2013 in the USA, 16.6 million adults (7.0 %) met
diagnostic criteria for an AUD and 6.8 % of the population engaged in heavy drinking (five or more drinks on
five or more days out of the past 30 days) [1]. AUDs and
heavy drinking are associated with car crashes, domestic
violence, neurocognitive impairments, poor medication
adherence, psychiatric comorbidity, and increased morbidity and mortality [2–8]. The total societal costs of
AUDs and heavy drinking, including health care costs,
law enforcement costs, other direct costs (e.g., material
losses due to accidents), and productivity losses were estimated in 2006 to be over $131 billion dollars, representing 1 % of the total US Gross Domestic Product [9].
Despite the high prevalence and costs associated with
AUDs, treatment rates in the general population remain
astonishingly low. In 2013, only 7.8 % of individuals
meeting diagnostic criteria for AUD received any AUD
treatment [6]. Improving access to evidence-based treatments for AUD has the potential to realize savings in
health care costs given the multiple chronic conditions
that are exacerbated by AUD and the high rate of accidental injury associated with heavy drinking and AUD.
The under-treatment of and costs associated with
AUD are also major problems within the Veterans
Health Administration (VHA). In fiscal year 2010, 360,729
VHA patients had an AUD diagnosis but only a third of
these patients received treatment in one of VHA’s 220 specialty addiction programs [10]. Yu and colleagues found
that the marginal yearly treatment cost (cost above the
mean for the entire sample) associated with a diagnosis of
an AUD was $3124 (1999 dollars) per patient [11].
Clearly, different models are needed to increase access
to treatment for the majority of individuals with AUD
that are not currently receiving treatment. Although the
need is great and interest in the integration of AUD
treatment into primary care settings is high, few models
for implementation of AUD treatment into primary care
have been tested. Pharmacotherapy for AUD using naltrexone or acamprosate is a vastly underutilized
evidence-based treatment for AUD that may have more
potential for integration into primary care settings relative to intensive behavioral or psychosocial treatments.
Randomized controlled trials and meta-analyses support
the efficacy of pharmacological treatment with naltrexone
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or acamprosate to improve drinking outcomes including
time to relapse, drinking days, and number of drinks per
drinking day [12–15]. Use of naltrexone or acamprosate
for patients with AUD is supported by National Quality
Forum’s National Voluntary Consensus Standards for the
Treatment of Substance Use Conditions published in
2007 and the VA-Department of Defense (DoD) Clinical
Practice Guidelines (CPG) for Management of Substance
Use Disorders (SUD) updated in 2009.
Despite the evidence supporting the use of naltrexone
and acamprosate for treating AUD, these medications
are underutilized in the USA [16]. While over 11 million
individuals in the USA met criteria for AUD in 2006 [6],
only an estimated 674,000 prescriptions were filled for
AUD medications (includes disulfiram as well as naltrexone and acamprosate) [16]. If each prescription was for
a unique individual (a highly unlikely scenario), then
only 6 % received pharmacotherapy.
Among the 440,000 VHA patients with a documented
AUD diagnosis in fiscal year 2012, only 5.8 % received
any approved AUD pharmacotherapy. There is also extreme variability in prescribing rates at the facility level.
The rate of pharmacotherapy for AUD among Veterans
who received AUD specialty care ranged from 0 to 20 %
by facility with substantially lower prescribing rates for
Veterans with no contact with AUD specialty care [17].
Extremely low prescribing rates and significant variation
across facilities suggests that significant gaps exist in access to these medications and that more could be done
to increase prescribing rates.
Diagnosing the causes of quality/performance gaps

Previous work conducted by team investigators has indicated that the most predominant barriers to implementation of AUD pharmacotherapy include (1) perceived
low patient demand, (2) pharmacy or formulary restrictions, (3) inadequate provider training in the use of
AUD medications, (4) lack of provider confidence in the
effectiveness of AUD medications, and (5) lack of patient
awareness of AUD medications [18, 19]. This foundational work has led to the identification of key strategies
to overcome these barriers and promote implementation
of AUD pharmacotherapy including (1) educating providers about the effectiveness and appropriate use of
AUD medications, (2) educating patients about AUD
medication options, (3) activating patients to discuss
AUD medication options with their providers, (4) increasing physician involvement in AUD treatment, (4)
identifying, training, and supporting local role models or
champions, and (5) facilitating connections between providers and local AUD specialists. This paper describes
the development of an implementation trial to increase
AUD pharmacotherapy prescribing rates in primary
care.
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Methods/design
This trial will examine the feasibility, acceptability, and
effectiveness of an implementation intervention to improve rates of AUD pharmacotherapy prescribing in primary care settings in three VHA facilities. The
intervention includes training local clinical champions to
provide education and support to primary care providers, an educational website that includes access to
provider-specific dashboards for case identification, and
mailing of educational materials to identified veterans.
The primary outcome is prescribing rates which will be
examined through an interrupted time-series analysis
with matched control comparisons. Formative evaluation
and a cost assessment will assess feasibility and acceptability of the intervention and inform quantitative
results.
Theoretical model

The theory of planned behavior was selected to further
guide the development of our intervention components
because the trial was designed to change individual behaviors: physicians’ decisions to discuss and prescribe
AUD medications and patients’ decisions to discuss
AUD pharmacotherapy with their provider [20]. The
theory of planned behavior hypothesizes that intention
to act is driven by one’s attitude toward the behavior,
one’s subjective perception of peer norms related to the
behavior, and one’s perceived behavioral control (ability
to perform the behavior). Combining the recommendations from the foundational description of barriers with
the theory of planned behavior, we selected the strategies
described in Table 1 for inclusion in our multifaceted
implementation intervention.
Selection and recruitment of sites

Three large VHA medical facilities were recruited to participate in this trial. Sites were chosen based on the
availability of SUD specialty care providers and Primary
Care Mental Health Integration (PCMHI) providers interested in training as local clinical champions. While
participating sites were somewhat above average in overall prescribing rates of AUD pharmacotherapy for VHA
medical facilities, very little of that prescribing was
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occurring outside of SUD specialty clinic settings where
only a fraction of patients with AUD diagnoses receive
treatment, indicating plenty of room for improvement in
our targeted population (Veterans with AUD seen in primary care clinics).
Phase 1: developmental formative evaluation

To understand patient perspectives on pharmacological
treatments for AUD and barriers and facilitators to their
use of pharmacological treatments, ten veterans with
self-identified alcohol misuse will be recruited for interviews at each site. Interview questions will be guided by
the theory of planned behavior to address attitudes toward AUD medications (including their perceived safety
and efficacy), perceived peer norms regarding AUD
medications, and perceived ability to discuss AUD medications with their provider and use the medications consistently and appropriately. Veterans will also have the
opportunity to review the patient educational materials
and will be queried regarding their likely response to receiving educational materials in the mail, any privacy
concerns they may have with this plan, alternative
methods of making the materials available, and any suggestions for additional information/materials that they
would find helpful.
To understand primary care providers’ perspectives on
pharmacotherapy for AUD and barriers and facilitators
to prescribing pharmacotherapy for AUD in primary
care settings, eight to ten primary care providers will be
recruited for interviews at each site. Interview questions
will be guided by the theory of planned behavior to address knowledge of and attitudes toward the use of AUD
medications, perceived peer norms regarding prescribing
AUD medications, and perceived ability to integrate
AUD pharmacotherapy into their practice. Interview
questions will also address Consolidated Framework for
Implementation Research (CFIR) constructs to identify
local barriers and facilitators to implementation that will
need to be addressed by the intervention [21]. Providers
will also have an opportunity to review the provider educational materials to provide their input as to which
tools and what formats of dissemination would be most
helpful. Finally, providers will have an opportunity to

Table 1 Multifaceted implementation intervention strategies
Local clinical champions

Primary care providers

Veterans

• 1.5-day collaborative learning session
• Monthly facilitation teleconferences
• On-demand access to national clinical
and implementation champions
• Access to website with patient and provider
educational materials
• Access to patient dashboard at facility level

• Educational outreach provided by local
champions in large group (Grand Rounds)
and small group (practice team) settings
• On-demand access to national and local
clinical champions
• Access to website with patient and provider
educational materials
• Access to patient dashboard at the provider level
• Reminder emails when new patients added to
provider level dashboard

• Patient educational materials mailed
to home address
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review the patient educational materials and will be informed of the intent to mail the materials to patients so
that they can express any concerns related to this strategy or suggest modifications to the strategy.
To understand how to best assist clinical champions
in their role, each site’s participating local clinical champions (SUD specialty care prescriber and PCMHI provider) will complete brief interviews to provide input
into the final planning of a collaborative learning session
which will serve as the starting point of the intervention.
Questions will assess whether and how prescribers currently use AUD medications in their practice, what they
want to learn about AUD pharmacotherapy, what formats they prefer for learning, and what they feel they
would need to learn to provide support to primary care
prescribers. These interviews will also include questions
related to CFIR constructs for the purpose of identifying
local barriers and facilitators to implementation.
Qualitative data collected during developmental interviews will be analyzed using rapid qualitative analysis
techniques so that the data can be used to inform the
final details of the intervention plan [22].
Phase 2: three site feasibility trial of a multifaceted
implementation intervention
Site champion intervention

The site champion intervention incorporates empirically
based education and implementation methods including
participatory and interactive education, follow-up, and
performance feedback [23–28].
Two site champions from each site (a SUD specialty
care prescriber and PCMHI provider) will be contacted
by the Project Coordinator to complete informed consent and their pre-training interview (describe above).
Once interviews are complete, we will schedule the inperson collaborative learning session. All efforts will be
made to ensure that both participants from each facility
are available to attend. While the session will include a
didactic component, the majority of the session will be
collaborative and involve group discussions. The goals of
the in-person collaborative session are to ensure that all
champions are knowledgeable about (1) identifying
risky/heavy drinking and AUDs, (2) brief interventions
for risky/heavy drinking, and (3) pharmacological and
behavioral treatment options for AUDs. Additional goals
are to (1) increase champions’ capability to facilitate the
consideration of AUD pharmacotherapy by primary care
prescribers at their site and (2) assist champions in identifying local options for providing disease care management for AUD patients receiving pharmacotherapy.
Following the in-person collaborative learning session,
attendees will receive external facilitation in the form of
monthly teleconference meetings for 9 months to review
the agreed upon outreach plans, monitor progress, and
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identify implementation barriers and strategies to overcome them. Additional resources such as an email group
and access to an external expert consultant upon request
will also be available during that time. Finally, the site
champions will receive quarterly feedback reports on the
prescribing rate at their site as well as at the other participating facilities. The external facilitators will address
the feedback reports and help champions interpret and
apply the information learned.
Primary care prescriber intervention

Veterans at each site who have received a diagnosis of
AUD or an Alcohol Use Disorders Identification Test—Consumption Questions (AUDIT-C) score of greater
than 8 in Outpatient Patient Care Encounter files within
the past 12 months, do not have an active prescription
for an AUD medication (naltrexone, acamprosate, or
disulfiram), and have an upcoming primary care appointment within the next 30 days will be identified on a
rolling basis (once per month for 9 months) for inclusion in the cohort. Once a veteran is included, their primary care provider will be identified and the provider’s
electronic contact information will be collected for the
purposes of providing real-time case identification for
primary care providers.
On a weekly basis during the 9-month intervention
period, the project web application will automatically
send email invitations to primary care prescribers at the
intervention sites that have a patient in the target cohort
scheduled in their clinic within the next 7 days. The
email will describe the project goals and design. It will
provide a link to the project website where prescribers
will have access to patient and provider educational materials and contact information for the national clinical
champions and the local SUD specialty care and PCMHI
champions. The provider will also be able to click on a
link to access the list of identified patients on their panel
with appointments upcoming in the next 7 days. Following the initial email, primary care providers will receive
an email alert when they have a new upcoming appointment with a patient with an AUD diagnosis.
Veteran intervention

Each month, veterans newly added to the cohort will be
mailed educational materials. Veterans will only be mailed
materials once during the intervention even if they qualify
for the cohort during more than 1 month. Patients will be
sent a cover letter presenting the mailing as general educational information for VHA patients including “tips” for
planning a conversation about their alcohol use with their
primary care provider and an educational brochure titled
Medication-Assisted Treatment for Alcohol Dependence
developed by the VHA Office of Informatics and Analytics
as part of a toolkit to support implementation of the
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VA/DoD Substance Use Disorders Clinical Practice
Guideline (http://www.healthquality.va.gov/guidelines/MH/
sud/SUDTool3PatientBookletFinalHiRes.pdf).
Evaluation

The evaluation includes (1) the quantitative evaluation
of the impact of the intervention on the primary outcome of AUD pharmacotherapy prescribing rate, (2) a
formative evaluation designed using Stetler’s four-phase
formative evaluation model [29], and (3) a cost
assessment.
Effectiveness of the implementation intervention

The primary evaluation of the intervention’s effectiveness will use an interrupted time-series design to compare post-intervention outcomes and trends to preintervention levels within the three intervention sites.
This approach is most powerful and provides the best
control for facility characteristics, because sites are compared to themselves. However, this approach is vulnerable to confusing intervention effects with secular trends
or disruptions that affect all sites in the system. Therefore, we will conduct sensitivity analyses using comparison sites as controls. For each intervention site, candidate
comparison sites will be identified by closely matching on
several variables including SUD specialty care and nonspecialty care AUD prescribing rates, overall AUD diagnosis rates, and facility size. One site will be randomly selected from the identified close matches for each
intervention site. Monitoring of prescribing trends will
occur exclusively through the use of available administrative data. No intervention or other activities will occur at
the comparison sites.
Primary hypothesis 1

The rate of receipt of AUD medications among directly
targeted patients will increase in magnitude after the onset of the intervention.
The primary outcome will be the proportion of veterans diagnosed with AUD on an encounter within the
past 12 months who have an upcoming primary care appointment who fill a prescription for AUD medications
within 1 month of the targeted appointment. This rate
will be calculated monthly for a 16-month preintervention period and then during the 9-month intervention period. Because the optimal timeframe for observing the desired outcome is unknown, sensitivity
analyses will be conducted on the follow-up duration
(e.g., 2- and 3-month post-primary care visit). Using a
mixed-effects, segmented logistic regression analysis, we
will evaluate if there are changes in either the level or
slope following the onset of the intervention.
Then, we will elaborate this model to add the comparison to the control sites. This helps protect against the
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threat of misinterpreting secular effects occurring in the
overall system as intervention effects. We will also conduct several other models to fully understand the effects
of this intervention, including models that (1) incorporate separate “start-up” (i.e., months 17–20) and evaluation (i.e., months 18–25) segments and (2) look beyond
month 25 to characterize a segment for postintervention sustainment.
Primary hypothesis 2

The rates of consultations made from primary care to
AUD specialty care and PCMHI among directly targeted
patients will increase in magnitude after the onset of the
intervention.
This analysis will be completely parallel to hypothesis
1 except the outcome will be the occurrence of a consultation to AUD specialty care or PCMHI for the targeted patients following the index primary care visit.
Data on consultations will be extracted from the consultation table in the VA Corporate Data Warehouse,
from which we can identify the requesting and requested
specialties and providers.
Secondary hypothesis 1

The rate of receipt of AUD medications will increase in
magnitude after the onset of the intervention for patients with AUD who are NOT targeted by the
intervention.
The intervention may work by different pathways and
influence the treatment received by patients who are not
directly targeted by the intervention (sent educational
materials prior to a primary care visit), especially
through the prescribing and other efforts of the trained
local champions. Therefore, we will evaluate trends and
changes in AUD medication prescribing rates in patients
diagnosed with AUD on an encounter within the past
12 months who have an upcoming non-primary care
mental health or AUD clinic appointment (and who are
not sent pre-primary care visit educational materials)
who then fill a prescription for AUD medications within
1 month of the targeted appointment. These analyses
will exclude the targeted patients. The sampling and
analysis for this hypothesis will be completely parallel to
hypothesis 1, except it is focused on the non-targeted
population, i.e., patients with AUD who have appointments in AUD or mental health clinics, but not primary
care.
Secondary hypothesis 2

The rate of active consideration of AUD medications, as
measured by chart review, will increase in magnitude
after the onset of the intervention.
Although the main goal of the intervention is to increase AUD pharmacotherapy prescribing rates, it is
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assumed that there will be a portion of patients who discuss pharmacological treatment options with their provider but do not start a prescription for some reason. It
is difficult to confirm the occurrence of such a conversation with administrative data; data on consideration may
be buried in progress notes, if it is documented at all.
Given that there is currently little information available
in the literature regarding the proportion of patients that
do not receive an AUD medication after a process of active consideration, we will conduct a parallel outcome
analysis (same approach as the primary hypothesis) except the outcome will be chart review determination of
whether active consideration of these medications occurred even if a prescription was never filled in a subsample of patients. This will provide some data on
whether the intervention had an impact on rates of consideration and, if so, how the increase in rates of consideration compared to the increase in rates of receipt. For
a random sample of 50 included patients each month,
we will use chart reviews to assess for rates of AUD
pharmacotherapy consideration as documented in the
progress notes of the targeted primary care visit. This
will also provide some preliminary data to address the
question of what proportion of patients would be expected to receive a prescription if routine consideration
was in place and what proportion of patients would reject AUD pharmacotherapy after discussing the option
with their provider. The chart review data will also provide information on reasons why a discussed pharmacological treatment option is not prescribed.
Formative evaluation

Formative evaluation involves a “rigorous assessment
process designed to identify potential and actual influences on the progress and effectiveness of implementation efforts” [29]. Formative evaluation can serve many
purposes over the course of an implementation project
including identifying modifications to implementation
efforts that may optimize opportunities for success, fostering an understanding of the causal events leading to
change and the specific components of the intervention
that most influenced outcomes, and informing future
similar implementation efforts [29]. Our formative
evaluation plan is guided by the four-phase model of formative evaluation identified by Stetler [29] which include
the developmental, implementation-focused, progressfocused, and interpretive phases described below. Table 2
provides a summary of data collection methods and
links each data source to the stage of formative evaluation that it primarily informs.
Developmental formative evaluation

Developmental formative evaluation occurs prior to the
start of an implementation intervention to determine the
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feasibility of the proposed implementation intervention
and to solicit input from stakeholders regarding strategies
for improving the intervention plan [29]. For the current
study, as described above, developmental formative evaluation information will be collected through preintervention veteran, primary care prescriber, SUD specialty care, and PCMHI provider interviews.
Implementation-focused formative evaluation

Implementation-focused formative evaluation occurs
during the process of implementation and focuses on
the discrepancies between the implementation plan and
its execution in order to document actual implementation processes and evaluate and measure actual exposure
to the intervention [29]. For the current project, examples of processes that will be documented include (1)
champion attendance at the monthly facilitation meetings, (2) the percentage of identified primary care prescribers that opened study emails and accessed links to
the study website and personalized feedback reports,
and (3) the number and types of outreach activities
with primary care prescribers that were initiated by
the champions.
Progress-focused formative evaluation

The purpose of progress-focused formative evaluation is
to monitor progress in terms of achieving implementation goals and performance targets to identify blocked
progress, allowing steps to be taken to optimize the momentum of the intervention [29]. For the current study,
progress-focused formative evaluation data will primarily
come from the follow-up facilitation meetings. Meetings
will focus on barriers to implementation and strategies
to address identified barriers. Non-attendance of participants from a particular site will be documented, and
outreach through individual calls or emails will be initiated to assess for stalled progress and offer assistance
with barriers. Additionally, quarterly feedback reports on
prescribing rates developed for participants will be
reviewed by project staff to assess for any outliers, either
low or high progress, so that individual outreach or positive feedback can be initiated.
Interpretive formative evaluation

Interpretive formative evaluation uses the information
collected from all of the other formative evaluation
stages as well as information collected at the end of the
project regarding the experiences of participants to clarify the meaning of successful or failed implementation
and to enhance understanding of an implementation
strategy’s impact [29]. Additional information that will
be collected at the end of the implementation intervention are follow-up interviews with the participating
champions and a sample of primary care providers. The
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Table 2 Data collection methods for each formative evaluation stage
Developmental
Pre-intervention patient interviews

X

Pre-intervention provider interviews

X

Implementation-focused

Progress-focused

Interpretive
X

Primary care email read receipts and website access

X

X

Monthly facilitation meeting attendance

X

X

Monthly facilitation meetingotes

X

X

Quarterly feedback reports

X

X

Post-intervention provider interviews

follow-up interviews will be guided by the CFIR which
provides a systematic framework for identifying potential
barriers and facilitators to implementation [21].
Formative evaluation data analysis techniques

While some formative evaluation data will be analyzed
using simple counts, e.g., number of facilitation meetings
attended and number of PC providers accessing their
dashboard, formative evaluation data will primarily be
analyzed using qualitative data analysis techniques.
Qualitative data will include the veteran interview transcripts, facilitation meeting notes, and the pre- and postintervention provider interview transcripts. All documents will be uploaded into a qualitative data analysis
program (NVivo) that enables researchers to mark
blocks of text with thematic codes and explore relationships among and between codes and participant groups.
Qualitative data will be coded thematically following
techniques described by Miles and Humberman [30].
Three research team members will independently review
the transcripts and develop an initial coding list. A deductive analysis approach will be used during the development of the initial coding list to focus codes on predetermined domains of interest including barriers to implementation, facilitators to implementation, strategies,
and recommendations for the improvement of the intervention, and relevance to CFIR constructs. Following development and refinement of the initial coding list,
coders will code each transcript using the list, and they
will also add open codes (inductive coding) to identify
important themes not represented by the predetermined domains. Consensus meetings will be held
for review of consistency in coding. Inconsistencies will
be resolved through mutual discussion and agreement.
Finally, representative quotes and associated codes that
represent key themes will be identified through consensus with the research team.

X

X

[31]. Despite strong and uniform research support for
the effectiveness of pharmacotherapy to treat AUD, and
the cost effectiveness of the treatment itself, a low-cost,
effective, and easily adopted intervention to improve
utilization has yet to be identified. The proposed intervention was designed to be easily scalable and relatively
inexpensive to implement.
First, we will estimate the costs of the intervention,
which will include the cost of the provider collaborative
learning session, the staff costs to host conference calls
and provide expert consultation, and the costs of distributing educational materials. We will track the time spent
providing the patient and clinician components. We will
also track the cost of supplies and travel. We will convert the time parameters into costs using national VHA
wages [32].
Second, we will compare the cost of the intervention
to the patients’ health care costs in a budget impact analysis. The goal of this analysis is to investigate how the
intervention would affect a facility’s 1- and 2-year budgets. We expect that the intervention will have a very
low marginal cost per patient but believe that it is important to document the cost for future implementation
work.
For the budget impact analysis, we will follow VHA
and national recommendations [33, 34] and use VHA
administrative data. We will segment the utilization and
cost data into categories of care [35] so that we can
understand the budgetary impact on primary care, mental health specialty care, SUD specialty care, and pharmacy costs. The budget impact analysis will utilize an
interrupted time-series design to understand how the
intervention affects downstream utilization. This econometric approach to estimating net benefits was discussed
by Hoch [36], and we used it to examine the return on
investment for SUD spending [37].
Trial status

Cost assessment

Studies have shown that AUD is associated with high
costs and that pharmacotherapy treatment can be costeffective compared to referral to AUD specialty care

Pre-intervention interviews have been completed. The
champion collaborative learning session has taken
place, and champions have engaged in local outreach
activities with their primary care providers. The 9-month
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intervention phase, which includes monthly veteran mailings and weekly primary care provider email alerts along
with the availability of on-demand consultation from local
and national clinical champions, is currently underway.

Discussion
The ADAPT-PC protocol provides a detailed description
of an implementation intervention to improve access to
evidence-based pharmacological AUD treatments in primary care settings as well as providing a detailed description of how implementation frameworks and
methods can be used to enhance the design, refinement,
and evaluation of an implementation intervention. If this
implementation intervention is successful, it will provide
a relatively low-cost, scalable model that builds on local
expertise and can be disseminated to additional VHA
medical facilities and elsewhere. The information gained
from this project is highly likely to be of interest to
health care systems beyond the VHA system which are
also seeking methods to integrate AUD treatment into
primary care settings. Increasing patient access to
evidence-based AUD treatment has the potential not
only to improve patient outcomes but also to realize savings in health care costs given the multiple chronic conditions that are exacerbated by AUD and the high rate
of accidental injury associated with heavy drinking and
AUD. If successful, the intervention may also serve as a
model for interventions designed to increase implementation of other evidence-based psychiatric interventions.
This project will also contribute to the growing body
of research examining the relationship between CFIR
constructs and implementation success. With the formative evaluation data we are collecting, we will be able to
examine whether key barriers and facilitators were consistent across sites or unique to sites, whether certain facilitators were necessary for successful implementation
or, conversely, whether certain barriers were predictive
of implementation failure. We will also be able to examine which pre-implementation barriers were mitigated
by the intervention and which were not addressed. Such
information will inform targeted enhancements to the
intervention and possibly allow for tailoring of the implementation strategy to pre-identified barriers in future
sites.
Limitations

The main limitation to this study is that it includes only
three medical centers, all within the VHA health care system. In addition, these sites were selected partially because
there was existing expertise in AUD pharmacotherapy
within the local substance use disorder treatment clinics.
Each site also had local PCMHI providers that were interested in assisting with implementation. Therefore,
generalizability to VHA medical centers without local
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AUD pharmacotherapy expertise, without PCMHI in
place and willing to assist, or to medical centers outside of
the VHA system may be limited.
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